Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | IDO1 | P14902 | 6/20 | 0.37 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.37 |
| ▸ | EPAS1 | Q99814 | 4/20 | 0.37 |
| ▸ | GAA | P10253 | 4/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | DHODH | Q02127 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | GLA | P06280 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22406349 | 0.92 | KDM4E (0.37) | KDM4EMAPTIDO1HIF1AEPAS1 | |
| SCHEMBL22406321 | 0.90 | GAA (0.41) | KDM4EMAPTIDO1HIF1AEPAS1 | |
| SCHEMBL30546683 | 0.90 | GAA (0.41) | KDM4EMAPTIDO1HIF1AEPAS1 | |
| SCHEMBL22426373 | 0.86 | KDM4E (0.36) | KDM4EMAPTIDO1HIF1AEPAS1 | |
| SCHEMBL22426417 | 0.85 | HIF1A (0.43) | KDM4EMAPTHIF1AEPAS1GAA | |
| SCHEMBL22406335 | 0.85 | NOTUM (0.34) | MAPTIDO1HIF1AEPAS1GAA | |
| SCHEMBL22426372 | 0.84 | CASP6 (0.37) | MAPTIDO1HIF1AEPAS1GAA | |
| SCHEMBL22426369 | 0.82 | GAA (0.43) | KDM4EMAPTIDO1HIF1AEPAS1 | |
| SCHEMBL22406358 | 0.82 | GAA (0.44) | MAPTIDO1HIF1AEPAS1GAA | |
| SCHEMBL22426268 | 0.81 | GAA (0.42) | KDM4EMAPTIDO1HIF1AEPAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3938364-B1 | COMPOUNDS FOR AND METHODS OF TREATING DISEASES | ALTERITY THERAPEUTICS LTD (AU) | 2023-08-23 | — | — | EP | disclosed |
| EP-3938364-B1 | COMPOUNDS FOR AND METHODS OF TREATING DISEASES | ALTERITY THERAPEUTICS LTD (AU) | 2023-08-23 | — | — | EP | disclosed |
| US-10941143-B2 | Imidazo [1,5-a]pyridine compounds and their use | Alterity Therapeutics Limited (AU) | 2021-03-09 | — | — | US | disclosed |
| US-10941143-B2 | Imidazo [1,5-a]pyridine compounds and their use | Alterity Therapeutics Limited (AU) | 2021-03-09 | — | — | US | disclosed |
| WO-2020186291-A1 | COMPOUNDS FOR AND METHODS OF TREATING DISEASES | Alterity Therapeutics Limited (AU) | 2020-09-24 | — | — | WO | disclosed |
| US-20200291021-A1 | COMPOUNDS FOR AND METHODS OF TREATING DISEASES | Alterity Therapeutics Limited (AU) | 2020-09-17 | — | — | US | disclosed |
| US-20200291021-A1 | COMPOUNDS FOR AND METHODS OF TREATING DISEASES | Alterity Therapeutics Limited (AU) | 2020-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10941143-B2 | Imidazo [1,5-a]pyridine compounds and their use | SNCA, PARK7, HTT | KDM4E 1124/4885MAPT 8/4885IDO1 56/4885 |
| US-20200291021-A1 | COMPOUNDS FOR AND METHODS OF TREATING DISEASES | SNCA, HTT, PARK7 | KDM4E 857/4885MAPT 5/4885IDO1 434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.